An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumorMartin Gore, David M. Gershenson, Raji Ganesan et al.|Gynecologic Oncology|2019Cited by 104
Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC).Martin Gore, David M. Gershenson, Allan Hackshaw et al.|Journal of Clinical Oncology|2015Cited by 35
Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) FrameworkDanielle Blunt, Steven Lane, Rosemary Harrup et al.|Blood|2024Cited by 0